Wednesday, March 05, 2025 | 02:05 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Alembic Pharma posts Q4 net of Rs 35 cr as India and US businesses grow

During the quarter, Alembic Pharma's US portfolio strengthened with the acquisition of the balance 40 per cent stake in Aleor Dermaceuticals

Alembic Pharmaceuticals ups its US game plan, acquires Orit
Premium

Alembic Pharmaceuticals

Vinay Umarji Ahmedabad
Alembic Pharmaceutical Ltd. (APL) posted a net profit of Rs 35 crore for the quarter ending March 31, 2022 after charging off non-recurring expenses of Rs. 188 crore, gaining from growth in its India and US businesses.

The company's India branded business was up by 25 per cent year-on-year (YoY) in Q4 of FY'22 at Rs 449 crore, up from Rs 358 crore in Q4 of previous fiscal year. APL's US generics business also grew by 17 per cent to Rs 557 crore in Q4 of FY'22 as against Rs 475 crore in Q4 of FY'21.

During the quarter, Alembic Pharma's US

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in